Defeat MSA Alliance Board of Directors is pleased to report some good news from Alterity Therapeutics on ATH434, a new drug being developed by the company for the treatment of Multiple System Atrophy.
“Alterity is on track to launch the Phase 2 trial of its lead clinical candidate ATH434 by the end of the calendar year. ATH434 is a small molecule drug being developed for Multiple System Atrophy (MSA), a form of atypical parkinsonism where iron plays a key role in pathogenesis by promoting α-synuclein aggregation. The scientific investigation of ATH434, along with the results from the Phase 2 study, will augment the development and optimization of novel compounds expected to emerge from the new patent.”
For the full report from Alterity, visit their press release here